Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

INTRA-CELLULAR THERAPIES, INC.

(ITCI)
  Report
Delayed Nasdaq  -  04:00:01 2023-02-06 pm EST
47.52 USD   -2.86%
01/13RBC Cuts Price Target on Intra-Cellular Therapies to $72 From $74, Maintains Outperform Rating
MT
01/09Intra-cellular Therapies, Inc. : Entry into a Material Definitive Agreement (form 8-K)
AQ
01/09Transcript : Intra-Cellular Therapies, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 11:15 AM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Analyst Recommendations on INTRA-CELLULAR THERAPIES, INC.
01/13RBC Cuts Price Target on Intra-Cellular Therapies to $72 From $74, Maintains Outperform..
MT
2022RBC Lifts Price Target on Intra-Cellular Therapies to $69 From $67, Maintains Outperfor..
MT
2022RBC Cuts Price Target on Intra-Cellular Therapies to $67 From $70, Maintains Outperform..
MT
2022Analyst recommendations: Snowflake, Vipshop, UIta Beauty, VF, Ad..
MS
2022Goldman Sachs Cuts Intra-Cellular Therapies to Neutral From Buy, Price Target to $49 Fr..
MT
2022Mizuho Securities Adjusts Intra-Cellular Therapies' Price Target to $72 From $75, Keeps..
MT
2022Needham Adjusts Intra-Cellular Therapies' Price Target to $67 from $65, Keeps Buy Ratin..
MT
2022Goldman Sachs Lowers Intra-Cellular Therapies' Price Target to $64 From $71, Maintains ..
MT
2022Mizuho Securities Initiates Intra-Cellular Therapies at Buy with $75 Price Target
MT
2022RBC Lifts Price Target on Intra-Cellular Therapies to $71 From $70, Maintains Outperfor..
MT
2022Mizuho Initiates Intra-Cellular Therapies With Buy Rating, $75 Price Target, Cites 'Add..
MT
2022UBS Initiates Coverage on Intra-Cellular Therapies With Buy Rating, $75 Price Target
MT
2022Piper Sandler Starts Intra-Cellular Therapies at Neutral With $59 Price Target
MT
2022SVB Leerink Adjusts Intra-Cellular Therapies Price Target to $70 From $65, Maintains Ou..
MT
2022RBC Capital Adjusts Intra-Cellular Therapies' Price Target to $70 From $65, Maintains O..
MT
2022SVB Leerink Adjusts Intra-Cellular Therapies' Price Target to $65 from $50, Keeps Outpe..
MT
2022RBC Raises Price Target on Intra-Cellular Therapies to $65 From $55, Maintains Outperfo..
MT
2022Needham Lifts Intra-Cellular Therapies Price Target to $65 From $59, Maintains Buy Rati..
MT
2022Goldman Sachs Starts Intra-Cellular Therapies at Buy With $64 Price Target
MT
2021RBC Boosts Price Target on Intra-Cellular Therapies to $55 From $50 as FDA Approves Cap..
MT
2021Jefferies Adjusts Price Target for Intra-Cellular Therapies to $85 From $70, Maintains ..
MT
2021Canaccord Genuity Adjusts Intra-Cellular Therapies PT to $88 From $81
MT
2021Needham Adjusts Price Target on Intra-Cellular Therapies to $59 From $55, Maintains Buy..
MT
2021SVB Leerink Adjusts Intra-Cellular Therapies' Price Target to $50 from $45, Keeps Outpe..
MT
2021RBC Lifts Price Target on Intra-Cellular Therapies to $50 From $48, Maintains Outperfor..
MT
2021Intra Cellular Therapies : RBC Raises Price Target on Intra-Cel..
MT
2021Intra Cellular Therapies : RBC Trims Price Target on Intra-Cell..
MT
2021Intra Cellular Therapies : Needham Starts Intra-Cellular Therap..
MT
2021Intra Cellular Therapies : Jefferies Adjusts Intra-Cellular The..
MT
2021Intra Cellular Therapies : RBC Capital Adjusts Intra-Cellular T..
MT
2021Intra Cellular Therapies : RBC Boosts Price Target on Intra-Cel..
MT
2021Intra Cellular Therapies : RBC Capital Adjusts Price Target on ..
MT
2021Intra Cellular Therapies : RBC Capital Adjusts Price Target on ..
MT
2020Intra Cellular Therapies : Cantor Fitzgerald Adjusts Price Targ..
MT
2020Intra Cellular Therapies : Goldman Sachs Starts Intra-Cellular ..
MT
2020Intra Cellular Therapies : BTIG Adjusts Intra-Cellular Therapie..
MT
2020Intra Cellular Therapies : RBC Capital Adjusts Intra-Cellular T..
MT
Upcoming event on INTRA-CELLULAR THERAPIES, INC.